Source comparison
CJC-1295 No DAC & Ipamorelin: Pharmacokinetic Comparison
Elimination Half-Life ~30 minutes ~2 hours CJC requires 2–3x daily dosing; ipamorelin can extend to 2x daily Peak Plasma Concentration 15–30 minutes post-injection 30–45 minutes post-injection Co-administer or stagger by ≤20 minutes for synergy Receptor Target
This comparison does not assign a generated winner or score.
- Elimination Half-Life
- ~30 minutes
- ~2 hours
- CJC requires 2–3x daily dosing; ipamorelin can extend to 2x daily
- Peak Plasma Concentration
- 15–30 minutes post-injection
- 30–45 minutes post-injection
- Co-administer or stagger by ≤20 minutes for synergy
- Receptor Target
- GHRH receptors (anterior pituitary)
- Ghrelin receptors (ghrelin mimetic)
- Complementary pathways. Synergistic GH release when timed correctly
- Volume of Distribution
- 0.3–0.5 L/kg
- ~0.6 L/kg
- Both remain primarily in plasma/extracellular fluid
- Primary Metabolism Route
- DPP-IV enzymatic degradation
- Plasma peptidases + hepatic proteolysis
- Both clear rapidly. No accumulation with standard dosing
- Off-Target Effects
- Minimal
- No prolactin/cortisol elevation (unlike GHRP-2/6)
- Ipamorelin safer for long-term protocols without hormonal disruption